BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 16170157)

  • 21. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD.
    D'Antiga L; Del Rizzo M; Mengoli C; Cillo U; Guariso G; Zancan L
    Liver Transpl; 2007 Mar; 13(3):343-8. PubMed ID: 17154402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival after post-transplant lymphoproliferative disease in children.
    Nathanson S; Debray D; Delarue A; Deschênes G
    Pediatr Nephrol; 2002 Aug; 17(8):668-72. PubMed ID: 12185479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
    Shapiro NL; Tang CG; Bhattacharyya N
    Laryngoscope; 2011 Aug; 121(8):1718-25. PubMed ID: 21792960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
    Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
    Kellie SJ; Boyce H; Dunkel IJ; Diez B; Rosenblum M; Brualdi L; Finlay JL
    J Clin Oncol; 2004 Mar; 22(5):846-53. PubMed ID: 14990640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S; Oertel S; LeBlond V; Riess H; Varoqueaux N; Dörken B; Trappe R
    Ann Hematol; 2007 Aug; 86(8):599-607. PubMed ID: 17522862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder.
    Campisi P; Allen UD; Ngan BY; Hawkes M; Forte V
    Otolaryngol Head Neck Surg; 2007 Aug; 137(2):296-300. PubMed ID: 17666259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR.
    Yancoski J; Danielian S; Ibañez J; Turconi A; Cuarterolo M; Zelazko M; Niesters Hubert GM
    J Clin Virol; 2004 Sep; 31(1):58-65. PubMed ID: 15288615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.